论文部分内容阅读
目的探讨研究对急性脑梗死患者采用重组组织型纤溶酶原激活剂(rt-PA)联合依达拉奉治疗的临床疗效及安全性。方法 100例经确诊的急性脑梗死患者,随机分为对照组和观察组,各50例。对照组患者仅应用rt-PA治疗,观察组患者则在rt-PA治疗基础上联合使用自由基清除剂(依达拉奉),将两组治疗后的临床效果、神经系统功能评分情况进行对比。结果观察组临床总有效率(96.00%)明显高于对照组(70.00%)(P<0.05);观察组患者3 d、1、2周NIHSS评分[(9.6±3.01)、(4.0±1.76)、(1.79±0.36)分]分均明显低于对照组患者[(15.0±4.45)、(9.0±3.55)、(5.6±2.12)分],差异有统计学意义(P<0.05)。结论采用rt-PA联合依达拉奉治疗急性脑梗死的临床效果极为良好,神经系统功能得以保护,脑血管疾病的致残和致死的发生率降低,建议广泛应用。
Objective To investigate the clinical efficacy and safety of recombinant tissue plasminogen activator (rt-PA) and edaravone in patients with acute cerebral infarction. Methods One hundred patients with confirmed acute cerebral infarction were randomly divided into control group and observation group, with 50 cases each. Patients in the control group were treated with rt-PA only, and patients in the observation group were treated with rt-PA in combination with free radical scavenger (edaravone) to compare clinical outcomes and neurological function scores after treatment . Results The total effective rate (96.00%) in the observation group was significantly higher than that in the control group (70.00%) (P <0.05). The NIHSS scores in the observation group at 3 days and 1,2 weeks [(9.6 ± 3.01) and (4.0 ± 1.76) (1.79 ± 0.36) points were significantly lower than those in the control group [(15.0 ± 4.45), (9.0 ± 3.55), (5.6 ± 2.12) points], respectively, with statistical significance (P <0.05). Conclusion The clinical effect of rt-PA combined with edaravone in the treatment of acute cerebral infarction is very good. The neurological function is protected. The incidence of disability and death of cerebrovascular diseases is reduced. It is suggested that it should be widely used.